Mohri M, Sata M, Gomi K, Maruyama Y, Osame M, Maruyama I
Laboratory for Pharmacology, Asahi Chemical Industry Co., Ltd, Shizuoka, Japan.
Lupus. 1997;6(7):590-6. doi: 10.1177/096120339700600706.
We developed a novel assay using human thrombomodulin (TM), which detected overall abnormalities in the protein C anticoagulant pathway (PC pathway). This assay indicates the degree of inhibition of prothrombinase by TM, which is represented as the percentage of prothrombinase inhibition by 25 ng/ml of TM, termed PIP25 (Prothrombinase Inhibition Percentage). We examined PIP25 in plasma samples from patients with systemic lupus erythematosus (SLE) with or without lupus anticoagulant (LA), patients with Behcet's disease (BD), and patients with miscellaneous thrombotic vasculitis and compared these with the PIP25 of plasma samples from healthy volunteers in Japan. The PIP25S were significantly lower in SLE alone (35.5 +/- 12.8%, P = 0.036) and SLE with LA (33.0 +/- 13.3%, P = 0.030) and BD (33.3 +/- 13.4%, P = 0.010) than those in healthy volunteers (43.5 +/- 10.7%). There was no significance between healthy PIP25 and those with miscellaneous thrombotic vasculitis (44.2 +/- 8.4%, P = 0.823). These results suggest that the abnormalities of the protein C anticoagulant pathway were present in patients with SLE(LA) and BD.
我们开发了一种使用人血栓调节蛋白（TM）的新型检测方法，该方法可检测蛋白C抗凝途径（PC途径）中的整体异常情况。此检测方法显示了TM对凝血酶原酶的抑制程度，用25 ng/ml TM对凝血酶原酶的抑制百分比来表示，称为PIP25（凝血酶原酶抑制百分比）。我们检测了患有或未患有狼疮抗凝物（LA）的系统性红斑狼疮（SLE）患者、白塞病（BD）患者以及其他血栓性血管炎患者血浆样本中的PIP25，并将其与日本健康志愿者血浆样本中的PIP25进行比较。单独SLE患者（35.5 +/- 12.8%，P = 0.036）、伴有LA的SLE患者（33.0 +/- 13.3%，P = 0.030）以及BD患者（33.3 +/- 13.4%，P = 0.010）的PIP25均显著低于健康志愿者（43.5 +/- 10.7%）。健康志愿者的PIP25与其他血栓性血管炎患者的PIP25之间无显著差异（44.2 +/- 8.4%，P = 0.823）。这些结果表明，SLE（LA）和BD患者存在蛋白C抗凝途径异常。
